RxDoctor Payments Data

Robin Moore, DO

Family Medicine · Houston, TXNPI 1770559270

Payments from drug & device makers

$7,831in general payments, 2019–2025

Across 369 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$682
  • Lilly USA, LLC$518
  • Inspire Medical Systems, Inc.$358
  • Takeda Pharmaceuticals U.S.A., Inc.$342
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$7,79299%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,831 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$48,784
Medicare patients
113
Services billed
1,581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$65,704
FarxigaDapagliflozin Propanediol30$30,293
JardianceEmpagliflozin22$30,110
MounjaroTirzepatide21$25,609
EliquisApixaban19$20,630
JanuviaSitagliptin Phosphate13$18,502
RybelsusSemaglutide17$18,281
TradjentaLinagliptin13$13,420
MyrbetriqMirabegron11$9,117
Atorvastatin Calcium239$2,960
Rosuvastatin Calcium170$2,673
Nebivolol Hcl31$2,531
Adderall XrDextroamphetamine/Amphetamine11$2,218
Amlodipine Besylate313$1,807
Losartan Potassium124$1,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,509$83,98659 claims
Boehringer IngelheimJardiance, Tradjenta$166$43,53035 claims
AstraZenecaFarxiga$1,124$30,29330 claims
Lilly USA, LLCMounjaro$518$25,60921 claims
PfizerEliquis$210$20,63019 claims
MerckJanuvia$111$18,50213 claims
Astellas Pharma US IncMyrbetriq$97$9,11711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →